Commemorating the Contributions of Cancer Research Greats
March 12, 2021, by Norman E. Sharpless, M.D.
Dr. Emil Freireich, who died in February 2021, working with a blood cell separator at MD Anderson Cancer Center.
Credit: National Cancer Institute
There are those moments, those events that make it the ideal time to stop and reflect on the past.
Such is the case with the passing of Dr. Emil Freireich, who died last month at the age of 93 in Houston, his long-time home. Having begun his career in the 1950s at NCI, Dr. Freireich went on to become one of the most accomplished physician–scientists to ever step into a lab or comfort a worried patient.
Mar 8, 2021
High-dose, accelerated radiotherapy brings better 2-year overall survival, with no added toxicity
In patients with limited stage, small-cell lung cancer (SCLC), hyperfractionated, accelerated, twice-daily thoracic radiotherapy (60 Gy) was feasible, and higher doses brought about significant improvements in two-year and median overall survival compared with the standard dose and schedule (45 Gy), with no additional toxicities, according to a study published in
“To our knowledge, the two-year overall survival in our trial is the highest reported in trials in limited stage SCLC, including all trials of high-dose, once-daily thoracic radiotherapy, and adds to the evidence suggesting that accelerated, hyperfractionated thoracic radiotherapy is the most effective approach in this disease,” wrote Bjørn Henning Grønberg, MD, of the Norwegian University of Science and Technology, Trondheim, Norway, and colleagues.
Amgen today announced that data from a multicenter, randomized Phase 3 study evaluating the efficacy, safety and tolerability of BLINCYTO ® compared with consolidation chemotherapy before allogeneic hematopoietic stem cell transplantation in pediatric patients with high-risk first-relapse B-cell precursor acute lymphoblastic leukemia were published in The Journal of the American Medical Association . 1 BLINCYTO …
Amgen (NASDAQ:AMGN) today announced that data from a multicenter, randomized Phase 3 study evaluating the efficacy, safety and tolerability of BLINCYTO ® (blinatumomab) compared with consolidation chemotherapy before allogeneic hematopoietic stem cell transplantation (alloHSCT) in pediatric patients with high-risk first-relapse B-cell precursor acute lymphoblastic leukemia (B-ALL) were published in The Journal of the American Medical Association (JAMA) . 1
Share this article
Share this article
THOUSAND OAKS, Calif., March 2, 2021 /PRNewswire/ Amgen (NASDAQ:AMGN) today announced that data from a multicenter, randomized Phase 3 study evaluating the efficacy, safety and tolerability of BLINCYTO
® (blinatumomab) compared with consolidation chemotherapy before allogeneic hematopoietic stem cell transplantation (alloHSCT) in pediatric patients with high-risk first-relapse B-cell precursor acute lymphoblastic leukemia (B-ALL) were published in
The Journal of the American Medical Association (JAMA).
1
BLINCYTO demonstrated significantly prolonged event-free survival (events were defined by relapse, death, second malignancy, or failure to achieve complete remission) compared with chemotherapy. After a median of 22.4 months follow-up, 69% of patients treated with BLINCYTO were alive and event-free compared with 43% of patients treated with chemotherapy. Additionally, following treatment with BLINCYTO, 93% of patients with MRD at baseli
Cabozantinib Effective in Treating Metastatic Kidney Cancer by Angela Mohan on February 15, 2021 at 3:21 PM
Cabozantinib was found most effective in treating patients with metastatic papillary kidney cancer, as per results of a SWOG Cancer Research Network trial.
These findings will be presented at ASCO s virtual 2021 Genitourinary Cancers Symposium 2021. The findings will be simultaneously published in
The Lancet.
There are currently no effective treatments for metastatic papillary kidney cancer, or metastatic pRCC, a rare subtype of kidney cancer. One study of 38 patients found that the average survival rate was eight months after diagnosis.
Sumanta Pal, MD, clinical professor of medical oncology at City of Hope, a comprehensive cancer center, and an investigator at SWOG, a cancer clinical trials group funded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), said there is hope for metastatic papillary kidney cance